A patient with a fulminant clinical course of disseminated intravascular coagulation (DIC) is described. The DIC was first manifested by neurological symptoms and later dominated by hemorrhagic phenomena. Bleeding manifestations were not controlled by treatment with heparin, later supplemented with ε-amino-caproic acid and fresh blood. The patient’s condition precluded the performance of extensive diagnostic procedures. On the assumption that malignancy was the underlying disease, cyclophosphamide and hydrocortisone were administered. In spite of intensive treatment the patient died. Autopsy revealed mesenteric lymph node metastases of a mucinous adenocarcinoma, probably originating in the colon. It is emphasized that in some patients with malignant disease, acute DIC is the presenting and the predominant symptom. In such patients the hemorrhagic manifestations may not be controlled unless the underlying neoplastic disease is detected and treated.

Keywords:
DIC, Mucinous Adenocarcinoma
This content is only available via PDF.
© 1974 S. Karger AG, Basel
1974
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.